Literature DB >> 12152110

MAP kinase 1/2 (Erk 1/2) and serine/threonine specific protein kinase Akt/PKB expression and activity in the human corpus cavernosum.

F Sommer1, T Klotz, D Steinritz, A Schmidt, K Addicks, U Engelmann, W Bloch.   

Abstract

Nitric oxide (NO) is an important mediator in the cavernosal smooth muscle relaxation that causes erections. The purpose of this study was to examine the existence, distribution and phosphorylation stage of two recently discovered key enzymes for NO regulation in human cavernosal tissue, the MAP Kinase 1/2 (Erk 1/2) and the serine/threonine specific protein kinase Akt/PKB. The expression of the enzymes was examined in corpus cavernosum specimens taken from both potent men and from patients with long-term impotence. There was a distinct difference in the activation stage of the MAP Kinase 1/2 (Erk 1/2) between endothelium and smooth muscle cells in potent patients. This finding gives evidence for a cell-type-specific regulation of the eNOS-dependent NO release. Furthermore, we found a higher basal level of active MAP Kinase 1/2 (Erk 1/2) in impotent patients. This finding gives the first evidence for an inhibitory influence of MAP Kinase 1/2 (Erk 1/2) on cavernosal eNOS activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152110     DOI: 10.1038/sj.ijir.3900856

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  8 in total

1.  Hyperglycemia-impaired aortic vasorelaxation mediated through arginase elevation: Role of stress kinase pathways.

Authors:  Surabhi Chandra; David J R Fulton; Ruth B Caldwell; R William Caldwell; Haroldo A Toque
Journal:  Eur J Pharmacol       Date:  2018-11-28       Impact factor: 4.432

2.  Erectile tissue molecular alterations with aging: differential activation of the p42/44 MAP Kinase pathway.

Authors:  Angela Castela; Raquel Soares; Fátima Rocha; Pedro Vendeira; Ronald Virag; Carla Costa
Journal:  Age (Dordr)       Date:  2010-07-14

3.  Metformin treatment improves erectile function in an angiotensin II model of erectile dysfunction.

Authors:  Hicham Labazi; Brandi M Wynne; Rita Tostes; R Clinton Webb
Journal:  J Sex Med       Date:  2013-07-24       Impact factor: 3.802

Review 4.  Posttranslational modification of constitutive nitric oxide synthase in the penis.

Authors:  Biljana Musicki; Ashley E Ross; Hunter C Champion; Arthur L Burnett; Trinity J Bivalacqua
Journal:  J Androl       Date:  2009-04-02

5.  DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum.

Authors:  Fernando S Carneiro; Fernanda R C Giachini; Victor V Lima; Zidonia N Carneiro; Kênia P Nunes; Adviye Ergul; Romulo Leite; Rita C Tostes; R Clinton Webb
Journal:  Can J Physiol Pharmacol       Date:  2008-06       Impact factor: 2.273

6.  [Sexual dysfunction at urinary incontinence].

Authors:  J B Korda; M Braun; U H Engelmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

7.  Activation of the NGF/TrkA signaling pathway attenuates diabetic erectile dysfunction.

Authors:  Yi Hou; Linpei Jia; Ying Zhang; Wei Ji; Hai Li
Journal:  Oncotarget       Date:  2017-11-11

Review 8.  Erectile Dysfunction: Key Role of Cavernous Smooth Muscle Cells.

Authors:  Iara Leão Luna de Souza; Elba Dos Santos Ferreira; Luiz Henrique César Vasconcelos; Fabiana de Andrade Cavalcante; Bagnólia Araújo da Silva
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.